Zentalis Pharmaceuticals ZNTL
NASDAQ ZNTL
$2.52 -0.09 (-3.45%)
At close: Oct 2, 2026 · 4:00 PM EDT

Zentalis Pharmaceuticals (ZNTL) Gains from Sales and Divestitures (2021 - 2025)

Updated

Zentalis Pharmaceuticals (ZNTL) reported Gains from Sales and Divestitures of $26,000 for Q4 2025, down 74.8% from the prior quarter.

Analysis

Zentalis Pharmaceuticals (ZNTL) Gains from Sales and Divestitures (2021 - 2025) Analysis & Trends

For FY2025, Zentalis Pharmaceuticals posted Gains from Sales and Divestitures of $660,000.

  • By year, Gains from Sales and Divestitures came in at $13,000 in FY2024, -$406,000 in FY2023, -$56,000 in FY2022 and -$15,000 in FY2021.
  • The Q4 2025 figure ranks as the lowest quarterly Gains from Sales and Divestitures since Q2 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Zentalis Pharmaceuticals 180.60 Mn 180.60 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 26,000.00
Sep 30, 2025 103,000.00
Jun 30, 2025 531,000.00
Jun 30, 2024 -53,000.00
Mar 31, 2024 66,000.00
Dec 31, 2023 -410,000.00
Jun 30, 2023 4,000.00
Dec 31, 2022 -124,000.00
Sep 30, 2022 125,000.00
Jun 30, 2022 -57,000.00
Mar 31, 2021 -15,000.00
API Access

Zentalis Pharmaceuticals Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=ZNTL&period=max&api_key=YOUR_API_KEY